BACKGROUND

Research on treatment satisfaction with treatments of multiple sclerosis (MS) is essential for delivering patient-centered care and improving treatment adherence. We aimed to review studies that have used the Treatment Satisfaction Questionnaire for Medication (TSQM) to assess treatment satisfaction with teriflunomide in patients with MS.

METHODS

PubMed, Scopus, Web of Science, PsycINFO, the Cochrane Library, and Google Scholar were searched by 2 independent reviewers to identify all relevant studies. Studies were selected based on the inclusion and exclusion criteria. The quality of observational studies was appraised using the 14-item National Institute of Health Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.

RESULTS

The search strategy was employed and 97 possible publications were found. After carefully reviewing the titles, abstracts, and full texts, a total of 9 articles have been selected for inclusion in the review. In all studies, teriflunomide had been prescribed in the treatment group, and in all studies, some patients had received previous disease-modifying therapies (DMTs). Study periods of all studies were between 3 months to 24 months. The results showed that all studies were of relatively high quality. In all studies, 4 domains of TSQM, especially the convenience domain, were improved after treatment with teriflunomide. Mean scores of the convenience domain in patients treated with teriflunomide were higher than other DMTs but some studies showed that some other DMTs may provide higher scores in other domains of TSQM.

CONCLUSION

Treatment with teriflunomide improves satisfaction in patients with MS.